Product category:
Pharmaceutical Processing News
News Release from: Frost and Sullivan | Subject: The HIV/AIDS Therapies Market
Edited by the Processingtalk Editorial
Team on 07 February 2003
The HIV/AIDS Therapies Market
While antiretroviral drugs in existing categories continue to be the mainstay of the HIV/AIDS therapies market in the United States, the development of new drugs offers exciting growth prospects
"Existing categories - nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) - as well as novel categories such as entry inhibitors, immune-based therapies, zinc finger inhibitors and integrate inhibitors have several drugs in the pipeline that can address the urgent requirement for new antiretroviral drugs," says Frost and Sullivan Research Analyst Raghunath Tantry A new analysis from Frost and Sullivan investigates the US HIV/AIDS Therapies Markets, revealing that revenues in this industry totalled $3.03 billion in 2002, and are projected to reach $10.88 billion by 2009
This article was originally published on Processingtalk on 24 Feb 2003 at 8.00am (UK)
Related stories
The European breast cancer pharmaceuticals market
The quest for a breast cancer wonder drug, and improved survival rates, continue to pump up business in the breast cancer pharmaceutical industry
Proteomics sample preparations markets
Integrated, customised, and validated research solutions for proteomics analyses and drug discoveries will fuel growth in the sample preparations market, according to the latest market resaerch report
Guided by the principles of highly active antiretroviral therapy (HAART), ARV drugs are usually recommended in combinations, which can increase the problem of pill burdens.
Such combinations require the patient to take many different tablets several times a day, creating a cumbersome situation and increasing the possibility of forgetting to take some of the tablets.
To combat this challenge, many manufacturers are researching the feasibility of reducing the number of tablets per day for various ARV drugs by enhancing tablet strength.
Significantly, the Food and Drug Administration has given its approval for some important drugs to be taken in smaller numbers and at longer intervals.
Rational fixed-dose combinations of the most recommended drugs belonging to one ARV category are another way of addressing this problem, seen in the GlaxoSmithKline merging of its NRTIs Epivir and Retrovir into a well accepted fixed-dose combination Combivir.
"Experts from the healthcare provider segments are hoping that in future, fixed dose combinations of ARVs that combine two NRTIs and one NNRTI or PI as per recommended guidelines will be available," says Tantry.
"This seems possible only if the manufacturers collaborate and synergise their core competencies in all three categories".
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
